Perspective Therapeutics logo

Perspective Therapeutics Share Price Today

(NASDAQ: CATX)

Perspective Therapeutics share price is $2.53 & ₹220.03 as on 6 Mar 2025, 2.30 'hrs' IST

$2.53

0.18

(7.66%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Perspective Therapeutics share price in Dollar and Rupees. Guide to invest in Perspective Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Perspective Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Perspective Therapeutics share price movements

  • Today's Low: $2.37
    Today's High: $2.57

    Day's Volatility :7.58%

  • 52 Weeks Low: $2.32
    52 Weeks High: $19.05

    52 Weeks Volatility :87.82%

Perspective Therapeutics (CATX) Returns

PeriodPerspective Therapeutics Inc.Index (Russel 2000)
3 Months
-31.99%
0.0%
6 Months
-83.61%
0.0%
1 Year
-75.2%
0.0%
3 Years
-33.42%
-11.6%

Perspective Therapeutics (CATX) Key Statistics

in dollars & INR

Previous Close
$2.35
Open
$2.4
Today's High
$2.565
Today's Low
$2.3707
Market Capitalization
$158.8M
Today's Volume
$681.3K
52 Week High
$19.05
52 Week Low
$2.32
Revenue TTM
$1.6M
EBITDA
$-55.8M
Earnings Per Share (EPS)
$-1.27
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-27.02%

How to invest in Perspective Therapeutics Stock (CATX) from India?

It is very easy for Indian residents to invest directly in Perspective Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Perspective Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Perspective Therapeutics or CATX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Perspective Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Perspective Therapeutics shares which would translate to 0.344 fractional shares of Perspective Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Perspective Therapeutics, in just a few clicks!

Returns in Perspective Therapeutics (CATX) for Indian investors in Rupees

The Perspective Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Perspective Therapeutics investment value today

Current value as on today

₹29,753

Returns

₹70,247

(-70.25%)

Returns from Perspective Therapeutics Stock

₹75,196 (-75.2%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Perspective Therapeutics (CATX)

-64%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Perspective Therapeutics Stock from India on INDmoney has decreased by -64% in the last 30 days, reflecting a downward trend in search activity.

Analyst Recommendation on Perspective Therapeutics

Buy

    87%Buy

    12%Hold

    0%Sell

Based on 8 Wall street analysts offering stock ratings for Perspective Therapeutics(by analysts ranked 0 to 5 stars)

Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Perspective Therapeutics Stock (CATX)

What analysts predicted

Upside of 534.39%

Target:

$16.05

Current:

$2.53

Insights on Perspective Therapeutics Stock (Ticker Symbol: CATX)

  • Price Movement

    In the last 6 months, CATX stock has moved down by -83.4%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.90M → 337.0K (in $), with an average decrease of 82.4% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -11.70M → -15.12M (in $), with an average decrease of 29.2% per quarter
  • CATX vs BSX (1 yr)

    In the last 1 year, Boston Scientific Corp. has given 55.3% return, outperforming this stock by 130.5%
  • Price to Sales

    ForCATX every $1 of sales, investors are willing to pay $87.2, whereas for Boston Scientific Corp., the investors are paying $9.2 for every $1 of sales.

Perspective Therapeutics Technicals Summary

Sell

Neutral

Buy

Perspective Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Perspective Therapeutics (CATX) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Perspective Therapeutics Inc. logo
-24.48%
-83.61%
-75.2%
-33.42%
-33.42%
Medtronic Plc logo
3.4%
5.22%
9.95%
-11.8%
1.8%
Edwards Lifesciences Corp. logo
2.13%
10.35%
-17.53%
-32.76%
14.39%
Boston Scientific Corp. logo
1.13%
28.68%
55.31%
146.09%
207.16%
Stryker Corporation logo
0.84%
10.53%
11.46%
56.15%
129.21%
Abbott Laboratories logo
6.67%
21.76%
15.39%
15.86%
78.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Perspective Therapeutics Inc. logo
NA
NA
NA
-0.85
-0.27
-0.14
NA
4.86
Medtronic Plc logo
28.71
28.71
1.91
5.45
0.08
0.05
0.03
38.49
Edwards Lifesciences Corp. logo
31.13
31.13
5.57
2.45
0.17
0.08
NA
16.99
Boston Scientific Corp. logo
84.24
84.24
1.87
2.86
0.09
0.05
NA
14.76
Stryker Corporation logo
50.77
50.77
2.91
13.49
0.15
0.07
0.01
54.1
Abbott Laboratories logo
18.34
18.34
2.52
5.15
0.31
0.06
0.02
27.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Perspective Therapeutics Inc. logo
Buy
$158.8M
-33.42%
NA
0.0%
Medtronic Plc logo
Buy
$119.3B
1.8%
28.71
12.83%
Edwards Lifesciences Corp. logo
Buy
$42.8B
14.39%
31.13
76.75%
Boston Scientific Corp. logo
Buy
$152.9B
207.16%
84.24
11.07%
Stryker Corporation logo
Buy
$148.8B
129.21%
50.77
13.25%
Abbott Laboratories logo
Buy
$238.6B
78.8%
18.34
31.95%

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.
Organization
Perspective Therapeutics
Employees
116
CEO
Mr. Johan M. Spoor
Industry
Miscellaneous

Management People of Perspective Therapeutics

NameTitle
Mr. Johan M. Spoor
CEO & Director
Mr. Jonathan R. Hunt
Chief Accounting Officer
Dr. Markus Puhlmann M.B.A., M.D.
Chief Medical Officer
Mr. Juan Graham
Chief Financial Officer
Mr. Shane Cobb
Executive Vice President of Operations
Dr. Michael K. Schultz Ph.D.
Chief Science Officer
Ms. Annie J. Cheng
Vice President of Investor Relations
Mr. Andrew Bright
Executive Vice President of Brachytherapy
Mr. Amos Hedt BA, PGradDip
Chief Business Strategy Officer
Mr. David Hauser Ph.D.
Senior Vice President of Clinical Operations

Important FAQs about investing in CATX Stock from India :

What is Perspective Therapeutics share price today?

Perspective Therapeutics share price today stands at $2.53, Open: $2.40 ; Previous Close: $2.35 ; High: $2.57 ; Low: $2.37 ; 52 Week High: $19.05 ; 52 Week Low: $2.32.

The stock opens at $2.40, after a previous close of $2.35. The stock reached a daily high of $2.57 and a low of $2.37, with a 52-week high of $19.05 and a 52-week low of $2.32.

Can Indians buy Perspective Therapeutics shares?

Yes, Indians can invest in the Perspective Therapeutics (CATX) from India.

With INDmoney, you can buy Perspective Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Perspective Therapeutics at zero transaction cost.

How can I buy Perspective Therapeutics shares from India?

It is very easy to buy Perspective Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Perspective Therapeutics (CATX) be purchased?

Yes, you can buy fractional shares of Perspective Therapeutics with INDmoney app.

What are the documents required to start investing in Perspective Therapeutics stocks?

To start investing in Perspective Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Perspective Therapeutics Stock (CATX)?

Today’s highest price of Perspective Therapeutics (CATX) is $2.57.

Today’s lowest price of Perspective Therapeutics (CATX) is $2.37.

What is today's market capitalisation of Perspective Therapeutics?

Today's market capitalisation of Perspective Therapeutics CATX is 158.8M

What is the 52 Week High and Low Range of Perspective Therapeutics Stock (CATX)?

  • 52 Week High

    $19.05

  • 52 Week Low

    $2.32

What are the historical returns of Perspective Therapeutics (CATX)?

  • 1 Month Returns

    -24.48%

  • 3 Months Returns

    -83.61%

  • 1 Year Returns

    -75.2%

  • 5 Years Returns

    -33.42%

Who is the Chief Executive Officer (CEO) of Perspective Therapeutics ?

Mr. Johan M. Spoor is the current Chief Executive Officer (CEO) of Perspective Therapeutics.